HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE: RCUS), a world clinical-stage biopharmaceutical firm targeted on growing differentiated molecules and mixture therapies for most cancers sufferers, at the moment introduced at the moment that the Compensation Committee of the Firm’s Board of Administrators granted 4 new workers choices to buy a complete of 66,900 frequent shares of the Firm at an train value per share of $15.96, which was the closing value on December 23, 2024, and restricted inventory items to accumulate a complete of 33,450 shares of frequent inventory of the Firm. The inventory awards have been granted pursuant to the Firm’s 2020 Incentive Plan, which was accredited by the Firm’s Board of Administrators in January 2020 pursuant to the Rule 303A Incentive Exception. 08 of the NYSE Listed Firms Handbook.
About Arcus Biosciences (NYSE:)
Arcus Biosciences is a world clinical-stage biopharmaceutical firm growing differentiated molecules and mixture medicines for individuals with most cancers. In partnership with trade collaborators, sufferers and physicians world wide, Arcus accelerates the event of first-in-class or higher medication in opposition to well-characterized organic targets and pathways and explores novel biology-based combos which have the potential to assist individuals with most cancers dwell longer. Based in 2015, the corporate has accelerated the event of a number of investigational medication to medical research, together with novel mixture approaches focusing on TIGIT, PD-1, HIF-2a, CD73, A2a/A2b twin receptor, CD39 and AXL. For extra info on Arcus Biosciences’ medical and preclinical applications, please go to www.arcusbio.com.
Incentive PR
Supply: Arcus Biosciences
View supply model on businesswire.com: https://www.businesswire.com/information/dwelling/20241224871937/en/
Investor requests:
Pia Eaves
Vice President of Investor Relations and Technique
(617) 459-2006
peaves@arcusbio.com
Media inquiries:
Holli Kolkey
Vice President of Company Communications
(650) 922-1269
hkolkey@arcusbio.com
Supply: Arcus Biosciences
#Arcus #Biosciences #Broadcasts #Employment #Incentive #Grants #Investing.com , #Gossip247
,
